A PHASE III, Randomized, Double-Blind, Placebo-Controlled study evaluating the efficacy and safety of GDC-0077 Plus Palbociclib and Fulvestrant Vs Placebo Plus Palbociclib and Fulvestrant in Patients with PIK3CA-mutant, Hormone Resceptor Positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.

  • Sabanathan, Dhanusha (Primary Chief Investigator)
  • Chapman, Nicola (Clinical Trial Unit Staff)

Project: Research

Project Details

Short titleINAVO120
AcronymWO41554
StatusActive
Effective start/end date15/12/2113/10/26